KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) was the target of unusually large options trading activity on Friday. Stock investors bought 33,499 call options on the company. This represents an increase of 18% compared to the typical daily volume of 28,364 call options.
Analyst Upgrades and Downgrades
Separately, Maxim Group started coverage on shares of KindlyMD in a research note on Wednesday, September 3rd. They issued a "buy" rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, KindlyMD currently has an average rating of "Buy" and a consensus target price of $8.00.
Check Out Our Latest Research Report on NAKA
KindlyMD Stock Performance
Shares of NASDAQ NAKA traded down $0.01 during midday trading on Wednesday, reaching $1.50. 31,321,217 shares of the company's stock traded hands, compared to its average volume of 4,360,491. The stock's 50 day moving average is $8.71. KindlyMD has a one year low of $0.65 and a one year high of $34.77. The stock has a market cap of $562.30 million, a P/E ratio of -1.74 and a beta of 33.96.
KindlyMD (NASDAQ:NAKA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.34) EPS for the quarter. KindlyMD had a negative net margin of 244.00% and a negative return on equity of 131.09%. The firm had revenue of $0.41 million for the quarter.
About KindlyMD
(
Get Free Report)
Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.
See Also
Before you consider KindlyMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KindlyMD wasn't on the list.
While KindlyMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.